APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bevacizumab

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Bevacizumab Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchBevacizumab Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Bevacizumab Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Bevacizumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bevacizumab Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Bevacizumab Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Bevacizumab market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Bevacizumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Bevacizumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Bevacizumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Bevacizumab market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Bevacizumab market include Mylan, Genentech, Amgen, MVASI (bevacizumab), Beacon Pharmaceuticals Limited, Balaji Medical Services Private Limited and Aark Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Bevacizumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Bevacizumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Bevacizumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Bevacizumab market size, projected growth trends, production technologies, key applications, and end-use industries.

Bevacizumab Segment by Company

Mylan

Genentech

Amgen

MVASI (bevacizumab)

Beacon Pharmaceuticals Limited

Balaji Medical Services Private Limited

Aark Pharmaceuticals

Bevacizumab Segment by Type

Avastin (bevacizumab)

Mvasi (bevacizumab-awwb)

Bevacizumab Segment by Application

Cancer

Eye Diease

Bevacizumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Bevacizumab status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Bevacizumab market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Bevacizumab significant trends, drivers, influence factors in global and regions.

6. To analyze Bevacizumab competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bevacizumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bevacizumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bevacizumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Bevacizumab market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Bevacizumab industry.

Chapter 3: Detailed analysis of Bevacizumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Bevacizumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Bevacizumab in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Bevacizumab Industry Trends Table 2. Bevacizumab Industry Drivers Table 3. Bevacizumab Industry Opportunities and Challenges Table 4. Bevacizumab Industry Restraints Table 5. Global Bevacizumab Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Bevacizumab Revenue Share by Company (2021-2026) Table 7. Global Bevacizumab Sales Volume by Company (k units) & (2021-2026) Table 8. Global Bevacizumab Sales Volume Share by Company (2021-2026) Table 9. Global Bevacizumab Average Price (US$/unit) of Company (2021-2026) Table 10. Global Bevacizumab Company Ranking, (2024-2026) & (USD Million) Table 11. Global Bevacizumab Key Company Manufacturing Base & Headquarters Table 12. Global Bevacizumab Company, Product Type & Application Table 13. Global Bevacizumab Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Bevacizumab by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Avastin (bevacizumab) Table 18. Significant Companies of Mvasi (bevacizumab-awwb) Table 19. Global Bevacizumab Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Bevacizumab Sales Volume by Type (2021-2026) & (k units) Table 21. Global Bevacizumab Sales Volume by Type (2027-2032) & (k units) Table 22. Global Bevacizumab Sales Volume Share by Type (2021-2026) Table 23. Global Bevacizumab Sales Volume Share by Type (2027-2032) Table 24. Global Bevacizumab Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Bevacizumab Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Bevacizumab Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Bevacizumab Sales Value Share by Type (2021-2026) Table 28. Global Bevacizumab Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Cancer Table 30. Significant Companies of Eye Diease Table 31. Global Bevacizumab Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Bevacizumab Sales Volume by Application (2021-2026) & (k units) Table 33. Global Bevacizumab Sales Volume by Application (2027-2032) & (k units) Table 34. Global Bevacizumab Sales Volume Share by Application (2021-2026) Table 35. Global Bevacizumab Sales Volume Share by Application (2027-2032) Table 36. Global Bevacizumab Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Bevacizumab Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Bevacizumab Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Bevacizumab Sales Value Share by Application (2021-2026) Table 40. Global Bevacizumab Sales Value Share by Application (2027-2032) Table 41. Global Bevacizumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Bevacizumab Sales by Region (2021-2026) & (k units) Table 43. Global Bevacizumab Sales Market Share by Region (2021-2026) Table 44. Global Bevacizumab Sales by Region (2027-2032) & (k units) Table 45. Global Bevacizumab Sales Market Share by Region (2027-2032) Table 46. Global Bevacizumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Bevacizumab Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Bevacizumab Sales Value Share by Region (2021-2026) Table 49. Global Bevacizumab Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Bevacizumab Sales Value Share by Region (2027-2032) Table 51. Global Bevacizumab Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Bevacizumab Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Bevacizumab Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Bevacizumab Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Bevacizumab Sales by Country (2021-2026) & (k units) Table 56. Global Bevacizumab Sales Market Share by Country (2021-2026) Table 57. Global Bevacizumab Sales by Country (2027-2032) & (k units) Table 58. Global Bevacizumab Sales Market Share by Country (2027-2032) Table 59. Global Bevacizumab Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Bevacizumab Sales Value Market Share by Country (2021-2026) Table 61. Global Bevacizumab Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Bevacizumab Sales Value Market Share by Country (2027-2032) Table 63. Mylan Company Information Table 64. Mylan Business Overview Table 65. Mylan Bevacizumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Mylan Bevacizumab Product Portfolio Table 67. Mylan Recent Development Table 68. Genentech Company Information Table 69. Genentech Business Overview Table 70. Genentech Bevacizumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Genentech Bevacizumab Product Portfolio Table 72. Genentech Recent Development Table 73. Amgen Company Information Table 74. Amgen Business Overview Table 75. Amgen Bevacizumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Amgen Bevacizumab Product Portfolio Table 77. Amgen Recent Development Table 78. MVASI (bevacizumab) Company Information Table 79. MVASI (bevacizumab) Business Overview Table 80. MVASI (bevacizumab) Bevacizumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. MVASI (bevacizumab) Bevacizumab Product Portfolio Table 82. MVASI (bevacizumab) Recent Development Table 83. Beacon Pharmaceuticals Limited Company Information Table 84. Beacon Pharmaceuticals Limited Business Overview Table 85. Beacon Pharmaceuticals Limited Bevacizumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Beacon Pharmaceuticals Limited Bevacizumab Product Portfolio Table 87. Beacon Pharmaceuticals Limited Recent Development Table 88. Balaji Medical Services Private Limited Company Information Table 89. Balaji Medical Services Private Limited Business Overview Table 90. Balaji Medical Services Private Limited Bevacizumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Balaji Medical Services Private Limited Bevacizumab Product Portfolio Table 92. Balaji Medical Services Private Limited Recent Development Table 93. Aark Pharmaceuticals Company Information Table 94. Aark Pharmaceuticals Business Overview Table 95. Aark Pharmaceuticals Bevacizumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Aark Pharmaceuticals Bevacizumab Product Portfolio Table 97. Aark Pharmaceuticals Recent Development Table 98. Key Raw Materials Table 99. Raw Materials Key Suppliers Table 100. Bevacizumab Distributors List Table 101. Bevacizumab Customers List Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Bevacizumab Product Image Figure 2. Global Bevacizumab Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bevacizumab Sales Value (2021-2032) & (US$ Million) Figure 4. Global Bevacizumab Sales (2021-2032) & (k units) Figure 5. Global Bevacizumab Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Bevacizumab Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Avastin (bevacizumab) Image Figure 10. Mvasi (bevacizumab-awwb) Image Figure 11. Global Bevacizumab Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Bevacizumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Bevacizumab Sales Volume Share by Type (2021-2032) Figure 14. Global Bevacizumab Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Bevacizumab Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Bevacizumab Sales Value Share by Type (2021-2032) Figure 17. Cancer Image Figure 18. Eye Diease Image Figure 19. Global Bevacizumab Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Bevacizumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Bevacizumab Sales Volume Share by Application (2021-2032) Figure 22. Global Bevacizumab Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Bevacizumab Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Bevacizumab Sales Value Share by Application (2021-2032) Figure 25. Global Bevacizumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Bevacizumab Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Bevacizumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Bevacizumab Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Bevacizumab Sales Value (2021-2032) & (US$ Million) Figure 30. North America Bevacizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Bevacizumab Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Bevacizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Bevacizumab Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Bevacizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Bevacizumab Sales Value (2021-2032) & (US$ Million) Figure 36. South America Bevacizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Bevacizumab Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Bevacizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Bevacizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Bevacizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Bevacizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Bevacizumab Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Bevacizumab Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Avastin (bevacizumab)
  • Mvasi (bevacizumab-awwb)
Applications
  • Cancer
  • Eye Diease
Companies covered
  • Mylan
  • Genentech
  • Amgen
  • MVASI (bevacizumab)
  • Beacon Pharmaceuticals Limited
  • Balaji Medical Services Private Limited
  • Aark Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Bevacizumab Sales Value (2021-2032)
  4. 1.2.2 Global Bevacizumab Sales Volume (2021-2032)
  5. 1.2.3 Global Bevacizumab Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Bevacizumab Market Dynamics
  1. 2.1 Bevacizumab Industry Trends
  2. 2.2 Bevacizumab Industry Drivers
  3. 2.3 Bevacizumab Industry Opportunities and Challenges
  4. 2.4 Bevacizumab Industry Restraints
3 Bevacizumab Market by Company
  1. 3.1 Global Bevacizumab Company Revenue Ranking in 2025
  2. 3.2 Global Bevacizumab Revenue by Company (2021-2026)
  3. 3.3 Global Bevacizumab Sales Volume by Company (2021-2026)
  4. 3.4 Global Bevacizumab Average Price by Company (2021-2026)
  5. 3.5 Global Bevacizumab Company Ranking (2024-2026)
  6. 3.6 Global Bevacizumab Company Manufacturing Base and Headquarters
  7. 3.7 Global Bevacizumab Company Product Type and Application
  8. 3.8 Global Bevacizumab Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Bevacizumab Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Bevacizumab Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Bevacizumab Market by Type
  1. 4.1 Bevacizumab Type Introduction
  2. 4.1.1 Avastin (bevacizumab)
  3. 4.1.2 Mvasi (bevacizumab-awwb)
  4. 4.2 Global Bevacizumab Sales Volume by Type
  5. 4.2.1 Global Bevacizumab Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Bevacizumab Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Bevacizumab Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Bevacizumab Sales Value by Type
  9. 4.3.1 Global Bevacizumab Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Bevacizumab Sales Value by Type (2021-2032)
  11. 4.3.3 Global Bevacizumab Sales Value Share by Type (2021-2032)
5 Bevacizumab Market by Application
  1. 5.1 Bevacizumab Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Eye Diease
  4. 5.2 Global Bevacizumab Sales Volume by Application
  5. 5.2.1 Global Bevacizumab Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Bevacizumab Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Bevacizumab Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Bevacizumab Sales Value by Application
  9. 5.3.1 Global Bevacizumab Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Bevacizumab Sales Value by Application (2021-2032)
  11. 5.3.3 Global Bevacizumab Sales Value Share by Application (2021-2032)
6 Bevacizumab Regional Sales and Value Analysis
  1. 6.1 Global Bevacizumab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Bevacizumab Sales by Region (2021-2032)
  3. 6.2.1 Global Bevacizumab Sales by Region: 2021-2026
  4. 6.2.2 Global Bevacizumab Sales by Region (2027-2032)
  5. 6.3 Global Bevacizumab Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Bevacizumab Sales Value by Region (2021-2032)
  7. 6.4.1 Global Bevacizumab Sales Value by Region: 2021-2026
  8. 6.4.2 Global Bevacizumab Sales Value by Region (2027-2032)
  9. 6.5 Global Bevacizumab Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Bevacizumab Sales Value (2021-2032)
  12. 6.6.2 North America Bevacizumab Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Bevacizumab Sales Value (2021-2032)
  15. 6.7.2 Europe Bevacizumab Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Bevacizumab Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Bevacizumab Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Bevacizumab Sales Value (2021-2032)
  21. 6.9.2 South America Bevacizumab Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Bevacizumab Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Bevacizumab Sales Value Share by Country, 2025 VS 2032
7 Bevacizumab Country-level Sales and Value Analysis
  1. 7.1 Global Bevacizumab Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Bevacizumab Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Bevacizumab Sales by Country (2021-2032)
  4. 7.3.1 Global Bevacizumab Sales by Country (2021-2026)
  5. 7.3.2 Global Bevacizumab Sales by Country (2027-2032)
  6. 7.4 Global Bevacizumab Sales Value by Country (2021-2032)
  7. 7.4.1 Global Bevacizumab Sales Value by Country (2021-2026)
  8. 7.4.2 Global Bevacizumab Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Bevacizumab Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Bevacizumab Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Bevacizumab Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Bevacizumab Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Bevacizumab Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Bevacizumab Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Bevacizumab Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Bevacizumab Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Bevacizumab Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Bevacizumab Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Bevacizumab Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Bevacizumab Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Bevacizumab Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Bevacizumab Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Bevacizumab Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Bevacizumab Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Bevacizumab Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Bevacizumab Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Bevacizumab Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Bevacizumab Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Bevacizumab Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Bevacizumab Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Bevacizumab Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Bevacizumab Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Bevacizumab Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Bevacizumab Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Bevacizumab Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Bevacizumab Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Bevacizumab Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Bevacizumab Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Bevacizumab Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Bevacizumab Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Bevacizumab Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Bevacizumab Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Bevacizumab Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Bevacizumab Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Bevacizumab Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Bevacizumab Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Bevacizumab Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Bevacizumab Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Bevacizumab Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Bevacizumab Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Bevacizumab Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Bevacizumab Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Bevacizumab Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Bevacizumab Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Bevacizumab Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Bevacizumab Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Bevacizumab Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Bevacizumab Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Bevacizumab Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Bevacizumab Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Bevacizumab Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Bevacizumab Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Bevacizumab Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Bevacizumab Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Bevacizumab Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Bevacizumab Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Bevacizumab Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Bevacizumab Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Bevacizumab Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Bevacizumab Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Bevacizumab Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Bevacizumab Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Bevacizumab Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Bevacizumab Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Bevacizumab Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Bevacizumab Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Bevacizumab Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Bevacizumab Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Bevacizumab Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Bevacizumab Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Bevacizumab Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Bevacizumab Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Bevacizumab Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Bevacizumab Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Bevacizumab Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Bevacizumab Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Bevacizumab Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Bevacizumab Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Bevacizumab Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Bevacizumab Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Bevacizumab Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Bevacizumab Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Mylan
  2. 8.1.1 Mylan Company Information
  3. 8.1.2 Mylan Business Overview
  4. 8.1.3 Mylan Bevacizumab Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Mylan Bevacizumab Product Portfolio
  6. 8.1.5 Mylan Recent Developments
  7. 8.2 Genentech
  8. 8.2.1 Genentech Company Information
  9. 8.2.2 Genentech Business Overview
  10. 8.2.3 Genentech Bevacizumab Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Genentech Bevacizumab Product Portfolio
  12. 8.2.5 Genentech Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen Bevacizumab Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Bevacizumab Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 MVASI (bevacizumab)
  20. 8.4.1 MVASI (bevacizumab) Company Information
  21. 8.4.2 MVASI (bevacizumab) Business Overview
  22. 8.4.3 MVASI (bevacizumab) Bevacizumab Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 MVASI (bevacizumab) Bevacizumab Product Portfolio
  24. 8.4.5 MVASI (bevacizumab) Recent Developments
  25. 8.5 Beacon Pharmaceuticals Limited
  26. 8.5.1 Beacon Pharmaceuticals Limited Company Information
  27. 8.5.2 Beacon Pharmaceuticals Limited Business Overview
  28. 8.5.3 Beacon Pharmaceuticals Limited Bevacizumab Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Beacon Pharmaceuticals Limited Bevacizumab Product Portfolio
  30. 8.5.5 Beacon Pharmaceuticals Limited Recent Developments
  31. 8.6 Balaji Medical Services Private Limited
  32. 8.6.1 Balaji Medical Services Private Limited Company Information
  33. 8.6.2 Balaji Medical Services Private Limited Business Overview
  34. 8.6.3 Balaji Medical Services Private Limited Bevacizumab Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Balaji Medical Services Private Limited Bevacizumab Product Portfolio
  36. 8.6.5 Balaji Medical Services Private Limited Recent Developments
  37. 8.7 Aark Pharmaceuticals
  38. 8.7.1 Aark Pharmaceuticals Company Information
  39. 8.7.2 Aark Pharmaceuticals Business Overview
  40. 8.7.3 Aark Pharmaceuticals Bevacizumab Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Aark Pharmaceuticals Bevacizumab Product Portfolio
  42. 8.7.5 Aark Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Bevacizumab Value Chain Analysis
  2. 9.1.1 Bevacizumab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Bevacizumab Sales Mode & Process
  6. 9.2 Bevacizumab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Bevacizumab Distributors
  9. 9.2.3 Bevacizumab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst